ARSENAULT KAITLYN has filed 15 insider transactions across 1 company since August 2023.
Most recent transaction: a grant/award of 125000 shares of Skye Bioscience, Inc. ($SKYE) on February 06, 2026.
Activity breakdown: 0 open-market purchases and 4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 6, 2026 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Stock Option (Right to Buy) | 125000 | $0.00 | 125,000.0000 | 39,665,927 | 9999.99% | 0.32% |
| Nov. 15, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | S | Common Stock | 190 | $5.55 | 210,548.0000 | 38,819,387 | 0.09% | 0.00% |
| Nov. 18, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | S | Common Stock | 43026 | $4.99 | 167,522.0000 | 38,819,387 | 20.44% | 0.11% |
| Feb. 24, 2025 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 36,486,519 | 9999.99% | 0.41% |
| Nov. 15, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | S | Common Stock | 190 | $5.55 | 209,548.0000 | 38,819,387 | 0.09% | 0.00% |
| Nov. 18, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | S | Common Stock | 43206 | $4.99 | 166,342.0000 | 38,819,387 | 20.62% | 0.11% |
| Oct. 28, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Stock Option (Right to Buy) | 125000 | $0.00 | 125,000.0000 | 38,819,387 | 9999.99% | 0.32% |
| Feb. 29, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Common Stock | 25000 | $0.00 | 209,738.0000 | 7,006,038 | 13.53% | 0.36% |
| Feb. 29, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 7,006,038 | 9999.99% | 1.07% |
| Feb. 29, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 7,006,038 | 9999.99% | 1.07% |
| Feb. 29, 2024 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Common Stock | 25000 | $0.00 | 210,738.0000 | 7,006,038 | 13.46% | 0.36% |
| Nov. 6, 2023 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Stock Option (Right to Buy) | 32053 | $0.00 | 45,436.0000 | 0 | 239.51% | 0.00% |
| Nov. 6, 2023 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Common Stock | 128209 | $0.00 | 185,738.0000 | 0 | 222.86% | 0.00% |
| Aug. 25, 2023 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Common Stock | 13382118 | $0.00 | 14,382,118.0000 | 0 | 1338.21% | 0.00% |
| Aug. 25, 2023 | Skye Bioscience, Inc. | $SKYE | ARSENAULT KAITLYN | Chief Financial Officer | A | Stock Option (Right to Buy) | 3345530 | $0.00 | 3,345,530.0000 | 0 | 9999.99% | 0.00% |